- Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMTThe Charcot-Marie-Tooth Association (CMTA), through its Strategy To Accelerate Research (STAR) initiative, is proud to support groundbreaking research that seeks to deepen our understanding of CMT2A and CMT2F, two axonal forms of Charcot-Marie-Tooth disease (CMT). ...Read more ...
- Let’s Beat CMT – 2024 CMT Awareness Month#LetsBeatCMT is a social media initiative during CMT Awareness Month to encourage the Charcot-Marie-Tooth disease community to share their CMT experiences throughout September. Post your videos and photos on social media using #LetsBeatCMT to educate the ...Read more ...
- CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2CThe Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news from our CMTA-STAR Alliance Partner, Actio Biosciences. The company has received both orphan drug designation (ODD) and rare pediatric disease designation (RPDD) designation from the ...Read more ...
- CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMTThe Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news from our CMTA-STAR Alliance Partner, Applied Therapeutics. The company plans to submit a New Drug Application (NDA) to the FDA for govorestat to treat CMT-SORD ...Read more ...
- Gene Replacement Therapy in CMT4 SubtypesThe Charcot-Marie-Tooth Association (CMTA) has announced a $240K investment in a groundbreaking gene replacement therapy for CMT4A, with potential applications for other types of CMT. This critical project is led by Xin Chen, MD, PhD, ...Read more ...
Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
